Pulse Biosciences

Pulse Biosciences is a medical technology company developing a novel tissue treatment platform based on its proprietary Nano-Pulse Stimulation technology. Nano-Pulse Stimulation is a non-thermal, precise, focal drug-free tissue treatment technology that initiates cell death within treated tissue. NPS utilizes nanosecond pulsed electric fields to induce cell signaling and the activation of cellular pathways by creating transient nanopores in cellular membranes and organelles. Once created, these transient nanopores allow ions to pass through these membranes, which disrupts cellular function and initiates cell death. NPS cell death eliminates treated tissue cells with a minimal inflammatory response, leading to a favorable healing process and the replacement of treated tissue cells with healthy tissue cells.

Type
Public
HQ
Burlingame, US
Founded
2014
Size (employees)
13 (est)
Pulse Biosciences was founded in 2014 and is headquartered in Burlingame, US

Pulse Biosciences Office Locations

Pulse Biosciences has an office in Burlingame
Burlingame, US (HQ)
104 849 Mitten Rd

Pulse Biosciences Data and Metrics

Pulse Biosciences Financial Metrics

USD

Net income (Q1, 2017)

(3.2 m)

Market capitalization (17-Aug-2017)

304.2 m

Cash (31-Mar-2017)

2.8 m
Pulse Biosciences's current market capitalization is $304.2 m.
USDFY, 2016

R&D expense

1.8 b

General and administrative expense

870 m

Operating expense total

2.8 b

Interest income

34 m

Net Income

(2.8 b)
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017

R&D expense

990 k1.5 m1.7 m1.9 m

General and administrative expense

528 k642 k893 k1.2 m

Operating expense total

1.5 m2.1 m2.6 m3.1 m

Interest income

3 k31 k39 k

Net Income

(1.7 m)(2.3 m)(2.8 m)(3.2 m)
USDFY, 2016

Cash

2.1 m

Inventories

268 k

Current Assets

16.7 m

Goodwill

2.8 m

Total Assets

26.3 m

Accounts Payable

265 k

Current Liabilities

1 m

Additional Paid-in Capital

37.9 m

Retained Earnings

(12.6 m)

Total Equity

25.3 m

Financial Leverage

1 x
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

2.1 m20.2 m4.6 m2.8 m

Current Assets

2.6 m21 m19 m19.1 m

Goodwill

2.8 m2.8 m2.8 m2.8 m

Total Assets

12.8 m31.1 m28.8 m28.6 m

Accounts Payable

296 k333 k446 k782 k

Current Liabilities

650 k590 k967 k1.2 m

Additional Paid-in Capital

16.9 m37.5 m37.7 m43.1 m

Retained Earnings

(4.8 m)(7 m)(9.8 m)(15.8 m)

Total Equity

12.2 m30.5 m27.9 m27.3 m

Financial Leverage

1.1 x1 x1 x1 x
USDFY, 2016

Net Income

(2.8 b)

Depreciation and Amortization

167 m

Inventories

12 k

Accounts Payable

29 k

Cash From Operating Activities

(101 k)

Purchases of PP&E

(46 k)

Cash From Investing Activities

(45 k)

Cash From Financing Activities

7.2 m
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(1.7 m)(2.3 m)(2.8 m)(3.2 m)

Depreciation and Amortization

166 k166 k166 k166 k

Accounts Payable

296 k333 k446 k782 k
Y, 2017

Financial Leverage

1 x

Pulse Biosciences Operating Metrics

Pulse Biosciences's Patent Applications was reported to be 61 in FY, 2016
FY, 2016

Patents Issued

49

Patent Applications

61

Pulse Biosciences Market Value History

Traffic Overview of Pulse Biosciences

Pulse Biosciences Company Life and Culture

You may also be interested in